Extremely fast !!! podes well for other contracts.
Thought the ER call was really positive. They got cash, coverage progressing, overwhelming response from patients and physicians and last but not least Inveltys is gaining market share in the post surgery segment.
Looking forward for more contract the coming weeks and months.
Why the lack of focus on regulatory approval for Eysuvis in EU and ROW, seems very casual.
News 
Market Data 
Discover 
